Posts tagged ‘Stockholm Cancer Congress’
Alpharadin may change standard of care for prostate cancer patients with bone mets
September 29th, 2011
Daedalus
We recently attended the 2011 European Multidisciplinary Cancer Congress in Stockholm. Paradigm shifting data in breast cancer and advanced prostate cancer were presented at what turned out to be an excellent meeting in a charming, if expensive, city.
Sally Church (@MaverickNY) live tweeted several sessions from the meeting and was name the “Top Twitter Influencer” for the #EMCC2011 hashtag. You can catch up with the tweets fron ECCO ESMO ESTRO 2011 on Pharma Strategy Blog.
Pieter Droppert (@3NT) has written several posts on biotech strategy blog about the exciting data for radium-223 (Alpharadin) in advanced prostate cancer that was presented in Stockholm.
He also produced a video of the media briefing by Dr Chris Parker from the Royal Marsden Hospital where the ALSYMPCA phase 3 trial results were reviewed. It is well worth watching!
Please contact us if you would like to learn more about the fast moving Prostate Cancer market and how pharma marketing strategy may be impacted by the new products in development such as radium-223 (Alpharadin), that is on fast track for FDA approval in 2012.
Next week sees the start of the 2011 Stockholm Cancer Congress – a joint multidisciplinary meeting of ECCO, ESMO and ESTRO.
What’s likely to be hot news from Stockholm? On Biotech Strategy Blog, Pieter Droppert has highlighted the phase III data to be presented at ECCO 2011 on Alpharadin (radium-223 chloride) in castration-resistant prostate cancer (CRPC).
The prostate cancer market is set to become interesting from a commercial and marketing strategy perspective, with several new products in late phase development for CRPC including MDV3100, TAK-700, lenalidomide, Alpharadin, custirsen, Prostvac to name but a few. The Alpharadin data from the ALSYMPCA trial will be presented as a late breaking abstract in the presidential session on Saturday September 24th. Based on the interim data previously released, positive data is expected.
The best abstract at ECCO 2011, however, is the data on hedgehog pathway (Hh) inhibitor, vismodegib in advanced basal cell carcinoma (BCC). This will also be presented in the presidential session on Saturday 24th.
Sally Church on Pharma Strategy Blog has written extensively about hedgehog inhibitors and earlier this week wrote about the news that Roche had filed for FDA approval of vismodegib. Given the accolade of “best abstract” and the data presented in the plenary session at the AACR annual meeting earlier this year, we can expect good news for patients who at present have no treatment options.
As Sally notes, vismodegib (GDC-0449) if approved by the FDA, “will offer the first proof of concept for the role of Hedgehog and Smoothend Inhibition in the treatment of cancer.”
Summer is almost over, and thoughts at Icarus Consultants are now turning to forthcoming medical meetings that we will be attending.
Photo: Max Anderson
We will be at ECCO 16 – ESMO 36 in Stockholm from September 23 – 27, 2011.
The jointly organized multidisciplinary cancer congress of the European CanCer Organisation (ECCO ) and European Society for Medical Oncology (ESMO) covers a wide range of topics from basic and translational science to surgery, radiotherapy, medical oncology, advocacy and care.
You can access the preliminary programme for the meeting here.
Given the early cut-off date for submission of abstracts for the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, we expect the ECCO/ESMO Stockholm meeting will publish interesting data on a number of new products in development.
In anticipation of the meeting, Sally Church will be analyzing the abstracts (once they are available) for what’s hot and you can expect a pre-meeting video blog post. If you missed Sally’s ASCO preview video, it is well worth watching.
Hope to see you in Stockholm.
Photo: Stan Shebs
